Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/bioresorbable-implant-advanced-materials-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Biomedical DevicesBioresorbable Implant Materials Patents: Who Holds the Claim Space
- Filing peaked in 2019 at 14 families and has since flattened, with the 2022 midpoint at 9 — this is a mature, occupied claim space rather than a growing one.
- Two assignees anchor the strongest co-filing pair in the dataset, Osteobiologics Inc and American Biomaterials Corp appear together nine times, more than any other pairing.
- A61L sterilising and coating claims cover 88 of 90 families, while alloy (C22C) and electroplating (C25D) subclasses sit far thinner — a gap for degradation-controlled metal work.
90
Published Records
56%
Top-5 Share of All Records
-100%
3-Yr Growth (lag-adjusted)
US
Leading Jurisdiction
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Overview
What this dataset covers
This landscape tracks 90 patent families filed between 2015 and mid-2026 that combine bioresorbable, biodegradable or resorbable implant claims with material-specific language: biodegradable magnesium alloys, PLGA scaffolds, degradation-controlled coatings, and general implant material composition. The search spans A61L27/58, C22C23 and A61L31, which together capture sterilising and coating treatments, alloy composition and implant material claims rather than device geometry or delivery mechanics.
Because publication lags filing by roughly 18 months, the 2025-2026 counts in the trend chart are undercounts, not a genuine drop-off. The more reliable signal is the plateau running from 2019 through 2022, which points to a field where the core material chemistries were staked out early and have not been substantially reopened since.
Filing activity and IPC composition, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Bioresorbable Implant Advanced Materials covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The data
Filing trend and technology composition
Two views of the same 90-family dataset: when the claims were filed, and which IPC subclasses they sit in.
Filing trend, 2017-2026
Filings rose to a peak of 14 in 2019, then eased toward the 2022 midpoint of 9. The partial 2026 count reflects publication lag, not a real collapse in filing activity — but the shape from 2019 onward is flat-to-declining rather than growing.
IPC subclass distribution
A61L (sterilising and disinfecting, largely coating and surface-treatment claims) dominates at 88 of 90 families, with A61F (implants and prostheses) as the second-largest bucket at 38. Alloy composition (C22C, 16) and electroplating/electroforming (C25D, 12) are present but thin relative to the coating layer, and dentistry-specific claims (A61C, 5) and casting process claims (B22D, 4) are the smallest groups tracked.
Shares are the percentage of the 90 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Bioresorbable Implant Advanced Materials covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Bioresorbable Implant Advanced Materials with Eureka
This page is one run against one query. Ask Eureka your own question about bioresorbable implant advanced materials and every answer comes back with the patent numbers behind it.
Try EurekaKey patents
Representative and most-cited filings
Representative filing
Magnesium alloy, biodegradable implant and method for producing a biodegradable implant
AAP IMPLANTATE AG
The filing claims a magnesium alloy composition with defined ranges for zinc, manganese and calcium content, including specific thresholds for manganese-or-calcium content and combined manganese-and-calcium content, with magnesium and impurities making up the balance. The claim structure ties implant biodegradability directly to the alloy's compositional ratios rather than to a separate coating step.Filed by AAP Implantate AG, published 2020-04-23 as US20200123636A1.
Most-cited records in this corpus
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5876452A | Biodegradable implant | 503 |
| 2 | US5716413A | Moldable, hand-shapable biodegradable implant material | 355 |
| 3 | US5492697A | Biodegradable implant for fracture nonunions | 291 |
| 4 | US5977204A | Biodegradable implant material comprising bioactive ceramic | 257 |
| 5 | US5863297A | Moldable, hand-shapable biodegradable implant material | 212 |
| 6 | US20030105530A1 | Biodegradable implant and method for manufacturing one | 137 |
| 7 | US6344496B1 | Biodegradable implant material comprising bioactive ceramic | 136 |
| 8 | US6203573B1 | Method of making biodegradable implant material and products made therefrom | 121 |
| 9 | WO1998046164A1 | Biodegradable implant material comprising bioactive ceramic | 71 |
| 10 | US20050240281A1 | Fiber-reinforced, porous, biodegradable implant device | 51 |
Citation counts favour older filings that have had longer to accumulate citations inside this corpus; read them as a signal of influence on the field's early foundations, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Bioresorbable Implant Advanced Materials covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing decision
Four read-outs from the trend, the citation table and the IPC split, oriented toward where new claims would actually land.
Filing momentum
14 in 2019, 9 at 2022 midpoint
peak vs. midpoint
The core chemistry window has closed
The steep rise to 2019 and the flattening since suggests the foundational composition claims — magnesium alloy ratios, PLGA scaffold formulations, base coating chemistries — were filed and consolidated inside a five-to-six-year window. New entrants are more likely to find freedom to operate in application-specific refinements than in base composition.
Filing trend, 2017-2026
Citation concentration
Top cited record: 503 citations
US5876452A
Old foundational patents still anchor freedom-to-operate review
The five most-cited records in this corpus were all filed well before the 2019 peak and describe moldable, hand-shapable biodegradable implant material and bioactive-ceramic composites. Any new material composition claim in this space should be checked against this cluster first, since citation weight this high usually means broad, frequently-referenced claim language.
Most-cited records table
IPC imbalance
A61L 88 vs. C25D 12
coating vs. electroforming families
Coating claims dominate; metal-forming claims are comparatively open
Sterilising and coating treatment claims (A61L) appear in nearly every family, while electroplating and electroforming process claims (C25D) sit at just 12. A degradation-controlled coating applied via an electroforming process, rather than dip- or spray-coating, is a combination this dataset does not show heavily claimed.
IPC subclass distribution
Co-filing structure
Strongest pair: 9 shared families
Osteobiologics + American Biomaterials
One partnership drove the field's early density
The strongest co-assignee pair in the dataset, at nine shared families, points to a single sustained research collaboration behind a large share of the foundational filings, rather than a broad field of independent competitors converging on the same chemistry.
Co-assignee pairs
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bioresorbable implant advanced materials, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Bioresorbable Implant Advanced Materials covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where momentum has gone quiet
Recent-year momentum across the tracked assignees is uniformly flat: every one of the leading names in this dataset shows zero filings in the latest tracked year, which is consistent with the field's overall plateau rather than a sign that any single competitor has pulled ahead recently.
Longest co-filing history
9 shared families
Osteobiologics + American Biomaterials
Osteobiologics Inc / American Biomaterials Corp
This pairing anchors the strongest co-assignee relationship in the corpus and sits behind several of the most-cited foundational patents on moldable biodegradable implant material.
Co-assignee pairs, strongest link
European alloy specialist
Representative filing 2020
AAP Implantate AG
AAP Implantate AG
Holds the representative magnesium-alloy filing in this dataset, with claims structured around compositional ratios of zinc, manganese and calcium rather than a separate surface treatment.
Representative record
Scaffold and fixation devices
0 filings in latest year
Bioretec
Bioretec
Tracked among the recent-momentum group with no filings in the most recent year, consistent with the broader plateau across all leading assignees in this corpus.
Recent-year momentum
Coating and surface treatment
0 filings in latest year
Meotec GmbH
Meotec GmbH
Active in the degradation-controlled coating space this dataset covers, though showing the same recent-year quiet as every other tracked assignee.
Recent-year momentum
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| OSTEOBIOLOGICS INC | 0 | — |
| AMERICAN BIOMATERIALS CORP | 0 | — |
| Inion Oy | 0 | — |
| BIORETEC | 0 | — |
| MEOTEC GMBH | 0 | — |
| Korea Institute of Materials Science | 0 | — |
| Jinwenshen Co., Ltd. | 0 | — |
| Board of Regents, The University of Texas System | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Bioresorbable Implant Advanced Materials covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's next
Where to take this analysis
The dataset points to a plateaued core and a thinner periphery. Two directions follow from that.
Stress-test a specific composition claim
Run a candidate magnesium alloy or PLGA formulation against the most-cited foundational records to see how close it sits to existing broad claims before drafting.
Run a claim comparison in EurekaMap the under-claimed combinations in detail
The electroforming and dental-alloy gaps identified here are IPC-level signals; a deeper family-by-family read is needed before committing to a filing strategy.
Explore white space in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Bioresorbable Implant Advanced Materials covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on bioresorbable implant material patents
The dataset shows filings rising to 14 in 2019 before flattening toward 9 at the 2022 midpoint. This pattern is typical of a field where foundational composition claims — for magnesium alloy ratios, PLGA scaffold formulations and base coating chemistries — get staked out in a concentrated window once the underlying material science matures enough for commercial-grade claims. After that window, new filings tend to shift toward narrower application-specific refinements rather than new base compositions, which shows up as a plateau rather than continued growth.
The most-cited records in this corpus, including US5876452A and US5716413A, describe moldable, hand-shapable biodegradable implant material and were filed well before the 2019 peak. High citation counts inside a searched corpus tend to favour older filings simply because they have had more time to accumulate citations, so treat this as a marker of foundational influence rather than a statement about who is most active today.
Both appear in this dataset, but the IPC split shows coating and sterilising treatment claims (A61L, 88 of 90 families) far outweighing alloy composition claims (C22C, 16 families). That does not mean magnesium alloy work is less commercially advanced; it means the surface-treatment and coating layer has attracted denser patent claiming, while alloy composition and metal-forming routes such as electroplating (C25D, 12) remain comparatively less crowded on the claims side.
This AAP Implantate AG filing, published April 2020, claims a magnesium alloy defined by specific weight-percent ranges for zinc, manganese and calcium, including thresholds on manganese-or-calcium content individually and combined. It ties degradability to the alloy's own composition rather than to a separate coating step, so it constrains anyone claiming a magnesium-zinc-manganese-calcium implant alloy within those same compositional bands — it does not on its own block coating-based or polymer-based approaches to controlling degradation.
Based on the IPC composition in this dataset, the thinnest tracked areas relative to the dominant coating and alloy-composition claims are electroforming-based degradation-controlled coatings, dental-specific resorbable alloy claims, and casting-process routes to graded porosity. These are signals from subclass density, not confirmed open ground — a full freedom-to-operate check against the specific claims in each family is still necessary before filing.
Answers are grounded in the same dataset. Derived from a Patsnap search on Bioresorbable Implant Advanced Materials covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Bioresorbable Implant Advanced Materials in depth with Eureka
Go past this page: query the whole bioresorbable implant advanced materials corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.